Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 pMDI in COPD (FRI Study)
NCT03268226Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Specific image-based airway volumes at 24 weeks and Specific image-based airway resistance at 24 weeks. Started Nov 2017; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03268226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268226.